Minute Insight: Inivata's RaDaR Assay Study Yields Encouraging Results
Executive Summary
RaDaR, a test for head and neck squamous cell carcinoma, demonstrated high efficacy in a new study.
You may also be interested in...
Minute Insight: Hedera DX Completes €14m Raise To Fund ML-Backed Liquid Biopsy Tech
Hedera DX’s liquid biopsy test uses machine learning to recommend drugs to patients based on a tumor’s circulating DNA profile.
NeoGenomics Bolsters Liquid Diagnostics Portfolio By Acquiring Inivata
Inivata will remain a separate liquid biopsy division alongside NeoGenomics’ growing clinical, pharma and informatics divisions.
Moving Pharma Execs Out Of The Shadows Is Key To Building Public Trust
2024 Rising Leader, Jack O’Meara, says the industry must ‘promote personalities’ when building new biotech businesses to gain the trust of investors and the public.